• ProRetina Therapeutics

    May 20, 2011

    ProRetina, spin-off of Biological Investigation Center (CSIC), GP Pharm Biopharmaceutical and BCN Peptides, fine chemicals division of Lipotec Group, have agreed to form a consortium to deal with the development of formulations that allow drugs to vehicular to the retina.

    The union aims to improve quality of patient’s life through the treatment of eye diseases such as retinitis pigmentosa and other retinal dystrophies. Download full Press Release